Mesothelioma Prognosis

Mesothelioma Prognosis
Individual Prognostic Factors & Scoring Systems
Median OS (Treated)	12–21 months
BAP1 Carrier Median OS	5 years
Best Scoring System	PLECH (AUC 0.70)
Under-50 5-Year Survival	39.2%
Female 5-Year Survival	13.4% vs. 4.5% male
Key Prognostic Factors	Stage, histology, PS, age, BAP1, NLR
Free Case Review →

Mesothelioma Prognosis

Overview

Mesothelioma prognosis describes the likely course and outcome of the disease for an individual patient, as distinct from population-level survival statistics. While overall median survival for treated pleural mesothelioma ranges from 12 to 21 months, individual prognosis varies dramatically based on measurable factors including disease stage, histologic subtype, performance status, age, gender, blood biomarkers, and molecular characteristics such as germline BAP1 mutations. Multiple validated prognostic scoring systems — including EORTC, CALGB, Brims, and the 2025 PLECH score — combine these variables to stratify patients into risk groups with significantly different survival expectations. Understanding individual prognostic factors helps patients make informed treatment decisions and empowers families to pursue appropriate legal compensation within applicable deadlines.

Mesothelioma prognosis at a glance:

• Treated patients survive 12–21 months on average — but individual outcomes vary dramatically based on stage, histology, age, gender, and molecular markers
• BAP1 mutation carriers survive 7 times longer — median 5 years compared to less than 1 year for non-carriers, making genetic testing critical
• Epithelioid subtype doubles survival — 14–18 months median versus 4–8 months for sarcomatoid, with 5-year rates of 14% versus 4%
• Women survive nearly 3 times longer — 13.4% five-year survival versus 4.5% for men, with 22% reduced mortality risk (HR 0.78)
• Age under 50 means 39% five-year survival — compared to just 4.5% for patients 75 and older, a nearly 9-fold difference
• PLECH score (2025) predicts survival most accurately — AUC 0.70 outperforms CALGB (0.60) and EORTC (0.57) scoring systems
• NLR ≥5 signals 2.7 times higher mortality — one-year survival drops from 60% to 26% based on this simple blood test ratio
• Peritoneal patients with complete surgery survive 8.7 years — median 104 months after cytoreductive surgery with HIPEC
• High-volume centers reduce surgical death by 31% — 10.0% versus 14.6% ninety-day mortality at specialized facilities

Key Facts

Key Facts: Mesothelioma Prognosis

Median Overall Survival: 12–21 months with active treatment; 7–8 months in population-based registries including untreated patients BAP1 Mutation Carriers: 7-fold improved long-term survival with median of 5 years versus less than 1 year for non-carriers Epithelioid vs. Sarcomatoid: 14–18 months vs. 4–8 months median survival; epithelioid 5-year survival approximately 14% vs. 4% for sarcomatoid Gender Difference: Women show HR 0.78 (22% reduced mortality risk) with 5-year survival of 13.4% vs. 4.5% for men Age Effect: Under 50: 39.2% five-year survival; 75+: 4.5% five-year survival — nearly 9-fold difference PLECH Score (2025): AUC 0.70 for 1-year overall survival prediction, outperforming CALGB (0.60) and EORTC (0.57) NLR Biomarker: Neutrophil-to-lymphocyte ratio ≥5 carries HR 2.7 — 1-year survival drops from 60% to 26% Peritoneal with CC-0: Complete cytoreduction achieves median 104 months (8.7 years) survival Performance Status: Independent predictor in every validated scoring system; ECOG 0–1 required for most curative-intent treatments Specialized Centers: High-volume facilities show lower 90-day mortality (10.0% vs. 14.6%, p=0.029) after mesothelioma surgery

What Factors Determine Mesothelioma Prognosis?

Mesothelioma prognosis is shaped by a combination of disease-related, patient-related, and treatment-related factors. Unlike many cancers where staging alone drives prognosis, mesothelioma outcomes depend on a broader constellation of variables that clinicians assess collectively.

Disease-Related Factors include the anatomic site (pleural, peritoneal, pericardial, or testicular), histologic subtype (epithelioid, sarcomatoid, or biphasic), disease stage at diagnosis, and molecular characteristics such as BAP1 mutation status. Peritoneal mesothelioma carries a fundamentally different prognosis than pleural disease, particularly when treated with cytoreductive surgery and HIPEC.

Patient-Related Factors encompass performance status (ECOG score), age at diagnosis, gender, nutritional status (serum albumin), and laboratory values including hemoglobin, white blood cell count, platelet count, lactate dehydrogenase (LDH), and the neutrophil-to-lymphocyte ratio (NLR). These measurable values form the basis of validated prognostic scoring systems.

Treatment-Related Factors include whether multimodal therapy is pursued, the completeness of surgical resection, access to immunotherapy, enrollment in clinical trials, and treatment at a high-volume specialized center. Patients who receive treatment at NCI-designated cancer centers with dedicated mesothelioma programs consistently achieve better outcomes.

ℹ Note: Prognosis is a statistical estimate based on groups of patients with similar characteristics — it does not predict what will happen to any individual. Some patients significantly outlive their predicted prognosis, particularly those with favorable molecular profiles such as BAP1 mutations.

How Do Prognostic Scoring Systems Predict Outcomes?

Four validated prognostic scoring systems have been developed specifically for mesothelioma, each combining multiple clinical variables to stratify patients into risk groups. These tools help oncologists set treatment expectations and guide decision-making about aggressive versus palliative approaches.

EORTC Prognostic Score (1998)

The European Organisation for Research and Treatment of Cancer score was the first validated mesothelioma prognostic model, developed from 204 patients across 5 phase II trials between 1984 and 1993.

Variables: Poor performance status, high white blood cell count, probable or possible histologic diagnosis, male gender, and sarcomatous histology.

Prognostic Group	Criteria	1-Year Survival
Good prognosis	2 or fewer of the 5 factors	40% (95% CI: 30–50%)
Poor prognosis	3 or more of the 5 factors	12% (95% CI: 4–20%)

The EORTC score was externally validated at St. Bartholomew's Hospital (n=145), showing median survival of 19.2 months for the good-prognosis group versus 9.9 months for poor-prognosis. However, in contemporary analyses, its discriminatory power is limited (AUC 0.57).

CALGB Prognostic Score (1998)

The Cancer and Leukemia Group B score was developed from 337 patients across 7 phase II clinical trials, using regression tree analysis to identify 6 prognostic groups based on performance status, age, chest pain, dyspnea, platelet count, weight loss, LDH, hemoglobin, white blood cell count, and histologic subtype.

The CALGB score was validated in a Leicester series (n=142) with results equivalent to the original data. Current AUC for 1-year overall survival prediction: 0.60.

Brims Decision Tree Model (2016)

Developed from 482 cases with 174-case external validation (2005–2014), the Brims model uses a decision tree approach with five variables: weight loss, hemoglobin, serum albumin, performance status, and histology.

Risk Group	18-Month Survival	Median Survival	Characteristics
Group 1 (best)	86.7%	34.0 months	No weight loss, Hb >153 g/L, albumin >43 g/L
Group 2	Intermediate	Intermediate	No weight loss, not meeting Group 1 lab criteria
Group 3	Intermediate	Intermediate	Weight loss present, PS 0–1, epithelioid histology
Group 4 (worst)	0%	7.5 months	Weight loss present, PS 0–1, sarcomatoid histology

The Brims model achieved a C-statistic of 0.761 (derivation) and 0.68 (validation) with 94.5% sensitivity. The British Thoracic Society endorses it as a clinical tool to consider at diagnosis.

PLECH Score (2025)

The newest and most accurate prognostic model, PLECH was developed from 262 patients at two cancer centers (2010–2023). Its name reflects the five weighted variables:

• Platelet count (high): +2 points
• LDH (high): +1 point
• ECOG ≥2: +1 point
• Chest pain at diagnosis: +2 points
• Non-epithelioid Histology: +1 point

Score range: 0–7 points. Optimal cut-off: 2.5.

Risk Group	Median OS	Median PFS
Low risk (score <3)	20.1 months	11.3 months
High risk (score ≥3)	12.3 months	6.4 months

The PLECH score achieved an AUC of 0.70 for 1-year overall survival prediction, outperforming both CALGB (0.60) and EORTC (0.57) in the same patient population.

"We advocate for early case evaluation because prognostic data directly informs legal strategy. A patient's scoring system results and biomarker profile shape not only treatment planning but also the urgency of filing claims before applicable deadlines expire."

— Paul Danziger, Founding Partner, Danziger & De Llano

What Role Do Blood Markers Play in Prognosis?

Several routine laboratory values serve as independent prognostic indicators in mesothelioma, many of which are incorporated into the scoring systems described above.

Biomarker	Direction	Impact	Evidence
Neutrophil-to-Lymphocyte Ratio (NLR)	NLR ≥5 = worse	HR 2.7; 1-year survival 26% vs. 60%	Meta-analysis, n=1,533
Platelet Count	High = worse	+2 points in PLECH score (highest weight)	PLECH 2025
LDH (Lactate Dehydrogenase)	High = worse	Independent predictor; +1 in PLECH	PLECH 2025, CALGB
Hemoglobin	Normal/high = better	Hb >153 g/L associated with Group 1 (best) prognosis	Brims 2016, EORTC
Serum Albumin	High = better	Albumin >43 g/L associated with best prognostic group	Brims 2016
White Blood Cell Count	High = worse	Leukocytosis independently predicts poor outcome	EORTC, SEER

These biomarkers are particularly valuable because they are measured through routine blood tests available at any medical facility and can be monitored throughout treatment to track disease trajectory.

How Do BAP1 Mutations Affect Long-Term Survival?

Germline BAP1 (BRCA1-associated protein 1) mutations represent the most significant molecular prognostic factor identified in mesothelioma, conferring dramatically improved long-term survival.

In a landmark study comparing 23 mesothelioma patients with germline BAP1 mutations to 10,556 SEER controls:

• Actuarial median survival: 5 years (versus less than 1 year for SEER controls)
• 5-year survival: 47% (95% CI: 24–67%) versus 6.7% (6.2–7.3%) in SEER
• 7-fold improved long-term survival, independent of sex and age
• Peritoneal BAP1 carriers: Median survival of 10 years
• Carriers with second malignancy: Median survival of 10 years

BAP1 carriers tend to develop epithelioid histology, respond exceptionally well to platinum-based chemotherapy, and demonstrate significantly enhanced chemosensitivity compared to sporadic mesothelioma cases.

✓ BAP1 Tumor Predisposition Syndrome: BAP1-TPDS (OMIM #614327) is an autosomal dominant hereditary cancer syndrome. Clinical practice guidelines (2023) recommend genetic counseling and surveillance for carriers, including regular imaging for mesothelioma detection. Given the improved survival in BAP1-associated mesothelioma, surveillance may allow earlier intervention and better outcomes.

A 2022 review by leading researchers noted that a fraction of BAP1 carrier patients "actually live 10 to 20 years and probably will not die of mesothelioma." This represents a fundamentally different disease biology with implications for treatment intensity, surveillance strategy, and long-term planning.

What Factors Can Improve a Patient's Prognosis?

While mesothelioma prognosis depends partly on immutable factors like age and gender, several modifiable factors can meaningfully influence outcomes:

Early-Stage Diagnosis: Stage I patients have 5-year survival of 33% versus 4% for Stage IV. Localized disease at SEER summary staging achieves 23% five-year relative survival.

Treatment at a Specialized Center: A National Cancer Database analysis (n=1,307) demonstrated that high-volume facilities achieve lower 30-day readmission rates (4.6% vs. 6.1%, p=0.021) and lower 90-day mortality (10.0% vs. 14.6%, p=0.029) compared to lower-volume centers.

Multimodal Treatment: Patients receiving surgery achieve median overall survival of 15 months versus 8 months without surgery (SEER data). The combination of chemotherapy, surgery, and repeat chemotherapy has achieved 3-year survival rates of 65% in selected patient populations.

Immunotherapy Access: The CheckMate 743 trial demonstrated that nivolumab plus ipilimumab achieves median overall survival of 18.1 months versus 14.1 months with chemotherapy alone, with 28% of responders maintaining response at 3 years compared to 0% with chemotherapy.

Clinical Trial Enrollment: Trial participants often receive cutting-edge treatments with rigorous monitoring. Both CheckMate 743 and the STELLAR trial (TTFields) demonstrated meaningful survival improvements over standard care.

Maintaining Performance Status: Good physical fitness (ECOG 0–1) is a prerequisite for most curative-intent therapies and is an independent predictor of survival across all validated scoring systems.

Who Are Long-Term Mesothelioma Survivors?

Long-term survival in mesothelioma is generally defined as surviving 5 or more years after diagnosis. At the population level, approximately 12–15% of pleural mesothelioma patients and up to 65% of peritoneal mesothelioma patients reach this milestone.

Characteristics of Long-Term Survivors

Analysis of published case series and National Cancer Database data reveals consistent patterns among mesothelioma long-term survivors:

• Younger age: Under 50: 5-year survival 39.2%, 10-year survival 33.4%
• Female gender: Independent predictor of improved survival (HR 0.78)
• Epithelioid histology: Predominates among long-term survivors
• Multimodal therapy: Surgery plus chemotherapy plus/minus radiation is the most common treatment among survivors
• Complete cytoreduction: CC-0 resection critical, particularly for peritoneal disease — median survival 104 months with CC-0 versus 30 months with CC-1
• Good performance status: ECOG 0–1 at diagnosis
• BAP1 germline mutation carriers: 47% five-year survival with molecularly favorable disease biology

In a NCDB analysis of 3,636 peritoneal mesothelioma patients, 17.8% (n=648) qualified as long-term survivors with a median survival of approximately 92 months. For peritoneal disease specifically, surgery plus HIPEC achieved the longest median overall survival (65.9 months) compared to surgery plus systemic therapy (38 months) or surgery alone (9.6 months).

How Does Age Affect Mesothelioma Prognosis?

Age at diagnosis is a continuous independent predictor of mesothelioma survival, with younger patients demonstrating dramatically better outcomes across all types and stages.

Age at Diagnosis	1-Year Survival	3-Year Survival	5-Year Survival	10-Year Survival
Under 50	68.6%	47.1%	39.2%	33.4%
50–64	54.9%	23.7%	15.3%	8.1%
65–74	38.1%	11.8%	6.4%	2.7%
75+	33.0%	9.3%	4.5%	1.7%

Source: NCI SEER database

Patients under 50 have nearly 9-fold better 5-year survival (39.2%) compared to those 75 and older (4.5%). This disparity reflects both disease biology — younger patients more frequently have BAP1-associated disease and peritoneal location — and the ability to tolerate aggressive multimodal treatment including surgery.

Young-onset mesothelioma (under 40) is more likely to be associated with germline BAP1 mutations, peritoneal rather than pleural location (especially in young women), or exposure to alternative mineral fibers such as erionite.

⚠ Important: Regardless of prognosis, statutes of limitations for mesothelioma lawsuits typically range from 1 to 6 years from diagnosis and do not pause based on treatment outcomes. Even patients with favorable prognostic profiles should consult with experienced mesothelioma attorneys promptly to preserve all legal options.

Frequently Asked Questions

What is the average prognosis for mesothelioma?

The average mesothelioma prognosis depends heavily on disease type, stage, and treatment. For pleural mesothelioma with active treatment, median overall survival is 12 to 21 months. Peritoneal mesothelioma treated with CRS/HIPEC can achieve median survival exceeding 50 months. Individual prognosis may differ significantly from averages based on the prognostic factors described on this page.

Can mesothelioma prognosis improve over time?

Yes. Treatment advances — particularly immunotherapy (nivolumab plus ipilimumab) and tumor treating fields (TTFields) — have meaningfully improved survival expectations since 2020. Additionally, patients with favorable prognostic profiles including epithelioid histology, early-stage diagnosis, and treatment at specialized centers consistently outperform population averages.

What is BAP1 and how does it affect prognosis?

BAP1 is a tumor suppressor gene. Patients carrying inherited (germline) BAP1 mutations develop a molecularly distinct form of mesothelioma with dramatically better prognosis — median survival of 5 years compared to less than 1 year for population controls. These patients show enhanced sensitivity to platinum-based chemotherapy and are more likely to survive long-term.

What is the PLECH score?

PLECH is the newest validated mesothelioma prognostic scoring system (2025), using five weighted variables: Platelet count, LDH, ECOG performance status, Chest pain, and non-epithelioid Histology. Scores range from 0 to 7, with scores below 3 (low risk) predicting 20.1 months median survival versus 12.3 months for scores of 3 or higher. It outperforms both the CALGB and EORTC scores in predicting 1-year overall survival.

Does gender affect mesothelioma prognosis?

Women with mesothelioma demonstrate approximately 50% better survival than men, with a hazard ratio of 0.78 for death and 5-year survival of 13.4% versus 4.5%. This difference may reflect hormonal factors, different exposure patterns (secondary versus occupational exposure), higher rates of epithelioid histology in women, and potentially different disease biology.

How does the neutrophil-to-lymphocyte ratio predict outcomes?

The NLR is a simple blood test ratio that serves as a powerful prognostic biomarker. An NLR of 5 or higher carries a hazard ratio of 2.7 for death, with 1-year survival dropping from 60% (NLR below 5) to just 26%. NLR can be monitored throughout treatment to track disease trajectory and treatment response.

Does treatment at a specialized center improve prognosis?

Research demonstrates that treatment at high-volume mesothelioma centers is associated with shorter hospitalization, lower readmission rates (4.6% vs. 6.1%), and lower 90-day mortality (10.0% vs. 14.6%). NCI-designated cancer centers with dedicated mesothelioma programs provide access to clinical trials, multidisciplinary teams, and high surgical volumes that improve outcomes.

Should mesothelioma patients get genetic testing for BAP1?

Clinical practice guidelines (2023, European Journal of Human Genetics) recommend genetic counseling and testing for patients with mesothelioma, particularly those diagnosed at younger ages, those with family history of mesothelioma or related cancers (uveal melanoma, renal cell carcinoma), and those with limited or no known asbestos exposure history. BAP1 status has implications for prognosis, treatment planning, and family member surveillance.

Quick Statistics

• 12–21 months median overall survival for treated pleural mesothelioma patients
• 5 years median survival for mesothelioma patients with germline BAP1 mutations versus less than 1 year for non-carriers
• 47% five-year survival rate among BAP1 mutation carriers compared to 6.7% in SEER population controls
• 39.2% five-year survival for patients diagnosed under age 50 versus 4.5% for those 75 and older
• 13.4% five-year survival for women versus 4.5% for men — women have 22% lower mortality risk
• 104 months median survival for peritoneal mesothelioma patients achieving complete cytoreduction (CC-0) with HIPEC
• 0.70 AUC achieved by the 2025 PLECH score for predicting 1-year overall survival, the most accurate mesothelioma prognostic model
• 2.7 hazard ratio for death when neutrophil-to-lymphocyte ratio exceeds 5, dropping 1-year survival from 60% to 26%
• 10.0% vs. 14.6% 90-day mortality at high-volume versus lower-volume mesothelioma surgery centers

Get Help

If you or a loved one has been diagnosed with mesothelioma, understanding your individual prognosis is a critical first step toward making informed treatment and legal decisions. Multiple prognostic factors can be assessed through routine medical evaluations to help guide your path forward.

Legal Resources:

• Danziger & De Llano — Experienced mesothelioma attorneys offering free case evaluations. Call (866) 222-9990 for a confidential consultation.
• Mesothelioma Lawyers Near Me — Find qualified mesothelioma attorneys in your area and access the free case evaluation quiz.
• Mesothelioma Lawyer Center — Legal resources and attorney matching services for mesothelioma families.
• Mesothelioma.net — Patient resources, treatment information, and support services.

Related Pages

Medical Information:

• Mesothelioma_Survival_Statistics — Population-level survival data and treatment outcome statistics
• Understanding_Your_Diagnosis — Guide to mesothelioma types, staging, and diagnosis
• Mesothelioma_Treatment_Centers — Specialized cancer centers with mesothelioma programs
• Clinical_Trials — Current research studies and enrollment opportunities
• CheckMate_743_Trial — Immunotherapy trial data for nivolumab plus ipilimumab

Quick Reference:

• Mesothelioma_Quick_Facts — Core statistics and essential data
• Veterans_Mesothelioma_Quick_Reference — VA benefits and military exposure data

Legal Resources:

• Mesothelioma_Claim_Process — Steps from diagnosis to compensation
• Statute_of_Limitations_by_State — State-by-state filing deadlines
• Asbestos_Trust_Funds — Trust fund information and filing guidance